Intellia Therapeutics to Present at September Healthcare Investor Conferences
27 Août 2018 - 2:00PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on the development of curative therapeutics using
CRISPR/Cas9 technology, will participate in the following upcoming
healthcare conferences in September:
Tuesday, September 4, 2018B. Riley FBR
Healthcare ConferencePanel: A Beginner’s Guide to Gene
TherapyLocation: New York, NYTime: 12:50pm ET
Wednesday, September 5, 2018Citi
Biotech ConferencePanel: Gene EditingLocation: Boston,
MassachusettsTime: 1:15pm ET
Thursday, September 6, 2018Wells Fargo
Healthcare ConferenceLocation: Boston, MassachusettsTime:
3:05pm ET
Thursday, September 27, 2018Jefferies
Gene Therapy SummitLocation: New York, NY
A live webcast of Intellia’s participation on the panel at the
Citi Biotech Conference and presentation at the Wells Fargo
Healthcare Conference will be accessible through the Events and
Presentations page of the Investor Relations section of the
company’s website at www.intelliatx.com. To access the webcasts,
please log on to the Intellia website approximately 15 minutes
prior to the start time to ensure adequate time for any software
downloads that may be required. A replay of the webcasts will be
available on Intellia’s website for approximately 14 days following
each conference.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology
has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course, and through improved cell therapies that can treat cancer
and immunological diseases by replacing patients’ diseased cells.
The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow
us on Twitter @intelliatweets.
Investor Contact:Lindsey Trickett Vice
President, Investor Relations +1
857-285-6211lindsey.trickett@intelliatx.com
Media Contact:Jennifer Mound SmoterSenior Vice
President, External Affairs & Communications+1
857-706-1071jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024